{
    "clinical_study": {
        "@rank": "112431", 
        "arm_group": [
            {
                "arm_group_label": "PRO-155", 
                "arm_group_type": "Experimental", 
                "description": "PRO-155 ophthalmic solution"
            }, 
            {
                "arm_group_label": "Nevanac", 
                "arm_group_type": "Active Comparator", 
                "description": "Nepafenac Ophthalmic Solution 0.1%"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution\n      PRO-155 in patients post phacoemulsification."
        }, 
        "brief_title": "Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cataract", 
        "condition_browse": {
            "mesh_term": "Cataract"
        }, 
        "detailed_description": {
            "textblock": "Postsurgical inflammation is an inevitable condition after cataract surgery. The use of\n      non-steroidal anti-inflammatory drugs is a safe option for treating ocular inflammation.\n\n      This is a phase II randomized double-blind clinical trial. The aim is to compare and to\n      evaluate efficacy and safety of two ophthalmic solutions in patients post\n      phacoemulsification. Patients will be randomized to receive either PRO-155 or Nevanac for 60\n      days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients older than 18 years who require cataract surgery\n\n          -  Both genders\n\n          -  Provide informed consent\n\n          -  Normal Laboratory results\n\n        Exclusion Criteria:\n\n          -  Patients with visual acuity of 20/40 or less in the contralateral eye of the surgery\n\n          -  Patients with any trans-surgical complication\n\n          -  Patients with a cataract >NC4, C4 or P4 classified with the system LOCS\n\n          -  Patients with any active corneal pathology\n\n          -  Patients under any steroidal treatment (topic, systemic or inhaled)14 days prior\n             surgery or NSAIDs 7 days before the surgery (except low-dose aspirin)\n\n          -  Patients with IOP <5 or >21 mmHg\n\n          -  Patients that have ocular pain, cellularity or flare at the moment of selection\n\n          -  Patients with ocular exfoliation, trauma or any inflammatory disease\n\n          -  Patients with diabetic retinopathy that need treatment or uncontrolled diabetes\n             mellitus\n\n          -  Patients who are planning cataract surgery of the contralateral eye 14 days after\n             surgery of the study eye\n\n          -  Patients with history of hypersensitivity or contraindication for any drug used in\n             the study\n\n          -  Patients under anticoagulant treatment\n\n          -  Contact lens users\n\n          -  Pregnant patients, at risk of pregnancy or breastfeeding\n\n          -  Patients without birth control treatment\n\n          -  Patients with any active toxicomanies (alcoholism, cigarette, cannabis or others)\n\n          -  Patients who had participated in any clinical trial in the last 90 days\n\n          -  Legal or mentally disabled patients who could not give informed consent\n\n          -  Patients who cannot comply with all study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657266", 
            "org_study_id": "SOPH155-0412/II"
        }, 
        "intervention": [
            {
                "arm_group_label": "PRO-155", 
                "description": "instill one drop 2 times a day (BID) for 30 days", 
                "intervention_name": "PRO-155", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nevanac", 
                "description": "instill one drop 2 times a day (BID) for 30 days", 
                "intervention_name": "Nevanac", 
                "intervention_type": "Drug", 
                "other_name": "Nepafenac"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "raulbustosz@yahoo.mx", 
                "last_name": "Raul Bustos, MD", 
                "phone": "36145501", 
                "phone_ext": "121"
            }, 
            "facility": {
                "address": {
                    "city": "Guadalajara", 
                    "country": "Mexico", 
                    "state": "Jalisco", 
                    "zip": "44280"
                }, 
                "name": "Hospital Civil de Guadalajara Fray Antonio Alcalde"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients", 
        "other_outcome": [
            {
                "description": "Number of patients with normal fluorescein dye", 
                "measure": "fluorescein dye", 
                "safety_issue": "Yes", 
                "time_frame": "day 60"
            }, 
            {
                "description": "Number of patients with normal green lissamine dye", 
                "measure": "green lissamine dye", 
                "safety_issue": "Yes", 
                "time_frame": "day 60"
            }
        ], 
        "overall_contact": {
            "email": "lbaiza@sophia.com.mx", 
            "last_name": "Leopoldo M Baiza-Dur\u00e1n, MD", 
            "phone": "+52(33) 30014200", 
            "phone_ext": "1051"
        }, 
        "overall_contact_backup": {
            "email": "clotilde.ayala@sophia.com.mx", 
            "last_name": "Clotilde Ayala-Barajas, MSc", 
            "phone": "+52(33) 30014200", 
            "phone_ext": "1074"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Federal Commission for Sanitary Risks Protection", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Change from Baseline in cellularity in anterior chamber after 60 days of treatment", 
                "measure": "cellularity in anterior chamber", 
                "safety_issue": "No", 
                "time_frame": "day 60"
            }, 
            {
                "description": "Change from Baseline in flare in anterior chamber after 60 days of treatment", 
                "measure": "flare in anterior chamber", 
                "safety_issue": "No", 
                "time_frame": "day 60"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657266"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of patients without pain, would be measured using the Visual Analog Pain Scale", 
            "measure": "Ocular pain", 
            "safety_issue": "No", 
            "time_frame": "day 60"
        }, 
        "source": "Laboratorios Sophia S.A de C.V.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Laboratorios Sophia S.A de C.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}